{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T08:22:28Z","timestamp":1794558148706,"version":"4.9.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Extremely premature infants are at risk for circulatory collapse or respiratory failure that are often treated with hydrocortisone (HC); however, there is no information on the metabolic consequences of this therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Longitudinal urine samples from infants &lt;28 weeks gestation in the Trial of Late Surfactant were analyzed by untargeted UHPLC:MS\/MS. Fourteen infants who received a tapering course of HC beginning at 3\u2009mg\/kg\/day for \u22659 days were compared to 14 matched control infants. A secondary cross-sectional analysis by logistic regression used urines from 314 infants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 1145 urinary metabolites detected, abundance of 219, representing all the major biochemical pathways, changed at <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05 in the HC-treated group with 90% decreasing; 3 cortisol derivatives increased ~2-fold with HC therapy. Only 11% of regulated metabolites remained responsive at the lowest HC dose. Regulated metabolites included two steroids and thiamin that are associated with lung inflammation in infants. HC responsiveness was confirmed in 57% of metabolites by cross-sectional analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>HC treatment of premature infants influenced in a dose-dependent manner abundance of 19% of identified urinary metabolites of diverse biochemical systems, primarily reducing concentrations. These findings indicate that exposure to HC reversibly impacts the nutritional status of premature infants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Impact<\/jats:title>\n                <jats:p><jats:list list-type=\"bullet\">\n                  <jats:list-item>\n                    <jats:p>Hydrocortisone treatment of premature infants with respiratory failure or circulatory collapse alters levels of a subset of urinary metabolites representing all major biochemical pathways.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>This is the first description of the scope, magnitude, timing and reversibility of metabolomic changes in infants in response to hydrocortisone, and it confirms corticosteroid regulation of three biochemicals that are associated with lung inflammatory status.<\/jats:p>\n                  <\/jats:list-item>\n                  <jats:list-item>\n                    <jats:p>The findings indicate a dose-dependency of hydrocortisone for metabolomic and anti-inflammatory effects, that prolonged therapy may lower the supply of many nutrients, and that monitoring concentrations of cortisol and inflammation markers may be a useful clinical approach during corticosteroid therapy.<\/jats:p>\n                  <\/jats:list-item>\n                <\/jats:list><\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41390-023-02610-5","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T17:02:37Z","timestamp":1683133357000},"page":"1317-1326","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The hydrocortisone-responsive urinary metabolome of premature infants"],"prefix":"10.1038","volume":"94","author":[{"given":"Dara","family":"Torgerson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Guardado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Steurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Chapin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan D.","family":"Hernandez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip L.","family":"Ballard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"2610_CR1","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1164\/ajrccm.163.7.2011060","volume":"163","author":"AH Jobe","year":"2001","unstructured":"Jobe, A. H. & Bancalari, E. Bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 163, 1723\u20131729 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2610_CR2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1164\/rccm.201612-2414OC","volume":"196","author":"LA Morrow","year":"2017","unstructured":"Morrow, L. A. et al. Antenatal determinants of bronchopulmonary dysplasia and late respiratory disease in preterm infants. Am. J. Respir. Crit. Care Med. 196, 364\u2013374 (2017).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2610_CR3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.pedneo.2019.09.005","volume":"60","author":"S Iijima","year":"2019","unstructured":"Iijima, S. Late-onset glucocorticoid-responsive circulatory collapse in premature infants. Pediatr. Neonatol. 60, 603\u2013610 (2019).","journal-title":"Pediatr. Neonatol."},{"key":"2610_CR4","first-page":"378","volume":"18","author":"S Mesiano","year":"1997","unstructured":"Mesiano, S. & Jaffe, R. B. Developmental and functional biology of the primate fetal adrenal cortex. Endocr. Rev. 18, 378\u2013403 (1997).","journal-title":"Endocr. Rev."},{"key":"2610_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0008-6363(98)00230-2","volume":"41","author":"ME Ullian","year":"1999","unstructured":"Ullian, M. E. The role of corticosteriods in the regulation of vascular tone. Cardiovasc. Res. 41, 55\u201364 (1999).","journal-title":"Cardiovasc. Res."},{"key":"2610_CR6","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1165\/rcmb.2004-0389OC","volume":"34","author":"KC Wade","year":"2006","unstructured":"Wade, K. C. et al. Gene induction during differentiation of human pulmonary type II cells in vitro. Am. J. Respir. Cell Mol. Biol. 34, 727\u2013737 (2006).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2610_CR7","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1165\/rcmb.2016-0068OC","volume":"55","author":"AM Barrette","year":"2016","unstructured":"Barrette, A. M. et al. Antiinflammatory effects of budesonide in human fetal lung. Am. J. Respir. Cell Mol. Biol. 55, 623\u2013632 (2016).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2610_CR8","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1542\/peds.110.2.285","volume":"110","author":"BJ Stoll","year":"2002","unstructured":"Stoll, B. J. et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 110, 285\u2013291 (2002).","journal-title":"Pediatrics"},{"key":"2610_CR9","first-page":"CD001145","volume":"10","author":"LW Doyle","year":"2017","unstructured":"Doyle, L. W., Cheong, J. L., Ehrenkranz, R. A. & Halliday, H. L. Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst. Rev. 10, CD001145 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"2610_CR10","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jpeds.2018.10.004","volume":"207","author":"ML Shaffer","year":"2019","unstructured":"Shaffer, M. L. et al. Effect of prophylaxis for early adrenal insufficiency using low-dose hydrocortisone in very preterm infants: an individual patient data meta-analysis. J. Pediatr. 207, 136\u2013142.e135 (2019).","journal-title":"J. Pediatr."},{"key":"2610_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/jama.2018.21443","volume":"321","author":"W Onland","year":"2019","unstructured":"Onland, W. et al. Effect of hydrocortisone therapy initiated 7 to 14 days after birth on mortality or bronchopulmonary dysplasia among very preterm infants receiving mechanical ventilation: a randomized clinical trial. JAMA 321, 354\u2013363 (2019).","journal-title":"JAMA"},{"key":"2610_CR12","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1056\/NEJMoa2114897","volume":"386","author":"KL Watterberg","year":"2022","unstructured":"Watterberg, K. L. et al. Hydrocortisone to improve survival without bronchopulmonary dysplasia. N. Engl. J. Med. 386, 1121\u20131131 (2022).","journal-title":"N. Engl. J. Med."},{"key":"2610_CR13","doi-asserted-by":"publisher","first-page":"a000588","DOI":"10.1101\/mcs.a000588","volume":"1","author":"CB Clish","year":"2015","unstructured":"Clish, C. B. Metabolomics: an emerging but powerful tool for precision medicine. Cold Spring Harb. Mol. Case Stud. 1, a000588 (2015).","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"key":"2610_CR14","doi-asserted-by":"publisher","first-page":"L810","DOI":"10.1152\/ajplung.00085.2018","volume":"315","author":"CV Lal","year":"2018","unstructured":"Lal, C. V. et al. Early airway microbial metagenomic and metabolomic signatures are associated with development of severe bronchopulmonary dysplasia. Am. J. Physiol. Lung Cell Mol. Physiol. 315, L810\u2013L815 (2018).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2610_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s11306-019-1482-9","volume":"15","author":"F Piersigilli","year":"2019","unstructured":"Piersigilli, F. et al. Identification of new biomarkers of bronchopulmonary dysplasia using metabolomics. Metabolomics 15, 20 (2019).","journal-title":"Metabolomics"},{"key":"2610_CR16","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/cts.12659","volume":"12","author":"T Lewis","year":"2019","unstructured":"Lewis, T., Chalise, P., Gauldin, C. & Truog, W. Pharmacometabolomics of respiratory phenotypic response to dexamethasone in preterm infants at risk for bronchopulmonary dysplasia. Clin. Transl. Sci. 12, 591\u2013599 (2019).","journal-title":"Clin. Transl. Sci."},{"key":"2610_CR17","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s41390-020-01343-z","volume":"90","author":"PL Ballard","year":"2021","unstructured":"Ballard, P. L. et al. Blood metabolomics in infants enrolled in a dose escalation pilot trial of budesonide in surfactant. Pediatr. Res. 90, 784\u2013794 (2021).","journal-title":"Pediatr. Res."},{"key":"2610_CR18","doi-asserted-by":"publisher","first-page":"898806","DOI":"10.3389\/fped.2022.898806","volume":"10","author":"B Stockard","year":"2022","unstructured":"Stockard, B., Gauldin, C., Truog, W. & Lewis, T. Pharmacometabolomics profiling of preterm infants validates patterns of metabolism associated with response to dexamethasone treatment for bronchopulmonary dysplasia. Front. Pediatr. 10, 898806 (2022).","journal-title":"Front. Pediatr."},{"key":"2610_CR19","doi-asserted-by":"publisher","first-page":"L870","DOI":"10.1152\/ajplung.00283.2017","volume":"315","author":"MR La Frano","year":"2018","unstructured":"La Frano, M. R. et al. Umbilical cord blood metabolomics reveal distinct signatures of dyslipidemia prior to bronchopulmonary dysplasia and pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol. 315, L870\u2013L881 (2018).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2610_CR20","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41390-020-0792-y","volume":"88","author":"CT McEvoy","year":"2020","unstructured":"McEvoy, C. T. et al. Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE). Pediatr. Res. 88, 629\u2013636 (2020).","journal-title":"Pediatr. Res."},{"key":"2610_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jpeds.2015.09.031","volume":"168","author":"RA Ballard","year":"2016","unstructured":"Ballard, R. A. et al. Randomized trial of late surfactant treatment in ventilated preterm infants receiving inhaled nitric oxide. J. Pediatr. 168, 23\u201329.e24 (2016).","journal-title":"J. Pediatr."},{"key":"2610_CR22","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1513\/AnnalsATS.201504-218OC","volume":"12","author":"BB Poindexter","year":"2015","unstructured":"Poindexter, B. B. et al. Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program. Ann. Am. Thorac. Soc. 12, 1822\u20131830 (2015).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"2610_CR23","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1203\/01.PDR.0000153947.51642.C1","volume":"57","author":"M Heckmann","year":"2005","unstructured":"Heckmann, M. et al. Assessing cortisol production in preterm infants: do not dispose of the nappies. Pediatr. Res. 57, 412\u2013418 (2005).","journal-title":"Pediatr. Res."},{"key":"2610_CR24","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.4155\/bio-2018-0182","volume":"10","author":"Y Wang","year":"2018","unstructured":"Wang, Y., Fujioka, N. & Xing, C. Quantitative profiling of cortisol metabolites in human urine by high-resolution accurate-mass MS. Bioanalysis 10, 2015\u20132026 (2018).","journal-title":"Bioanalysis"},{"key":"2610_CR25","doi-asserted-by":"publisher","first-page":"105774","DOI":"10.1016\/j.jsbmb.2020.105774","volume":"205","author":"R Wang","year":"2021","unstructured":"Wang, R., Hartmann, M. F. & Wudy, S. A. Targeted LC-MS\/MS analysis of steroid glucuronides in human urine. J. Steroid Biochem. Mol. Biol. 205, 105774 (2021).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"2610_CR26","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1111\/j.1442-200X.2011.03372.x","volume":"53","author":"M Mizobuchi","year":"2011","unstructured":"Mizobuchi, M., Yoshimoto, S. & Nakao, H. Time-course effect of a single dose of hydrocortisone for refractory hypotension in preterm infants. Pediatr. Int. 53, 881\u2013886 (2011).","journal-title":"Pediatr. Int."},{"key":"2610_CR27","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s00109-021-02076-0","volume":"99","author":"A Vega-Beyhart","year":"2021","unstructured":"Vega-Beyhart, A. et al. Endogenous cortisol excess confers a unique lipid signature and metabolic network. J. Mol. Med. (Berl.) 99, 1085\u20131099 (2021).","journal-title":"J. Mol. Med. (Berl.)"},{"key":"2610_CR28","first-page":"34","volume":"30","author":"PC Papagianis","year":"2019","unstructured":"Papagianis, P. C., Pillow, J. J. & Moss, T. J. Bronchopulmonary dysplasia: pathophysiology and potential anti-inflammatory therapies. Paediatr. Respir. Rev. 30, 34\u201341 (2019).","journal-title":"Paediatr. Respir. Rev."},{"key":"2610_CR29","doi-asserted-by":"publisher","first-page":"e0182685","DOI":"10.1371\/journal.pone.0182685","volume":"12","author":"K Ivars","year":"2017","unstructured":"Ivars, K. et al. Development of salivary cortisol circadian rhythm in preterm infants. PLoS One 12, e0182685 (2017).","journal-title":"PLoS One"},{"key":"2610_CR30","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1172\/JCI108236","volume":"56","author":"PL Ballard","year":"1975","unstructured":"Ballard, P. L., Granberg, P. & Ballard, R. A. Glucocorticoid levels in maternal and cord serum after prenatal betamethasone therapy to prevent respiratory distress syndrome. J. Clin. Invest. 56, 1548\u20131554 (1975).","journal-title":"J. Clin. Invest."},{"key":"2610_CR31","doi-asserted-by":"crossref","unstructured":"Kakkilaya, V. & Gautham, K. S. Should less invasive surfactant administration (LISA) become routine practice in US neonatal units? Pediatr. Res. 93, 1188\u20131198 (2023).","DOI":"10.1038\/s41390-022-02265-8"},{"key":"2610_CR32","doi-asserted-by":"crossref","unstructured":"Guardado, M., Steurer, M., Torgerson, D., Chapin, C. & Ballard, P. L. Urinary metabolomic fingerprint in extremely preterm infants on parenteral versus oral feeds. Pediatric Academic Societies Meeting (2022).","DOI":"10.20944\/preprints202307.2091.v1"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-023-02610-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-023-02610-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-023-02610-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T11:04:32Z","timestamp":1697799872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-023-02610-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["2610"],"URL":"https:\/\/doi.org\/10.1038\/s41390-023-02610-5","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"24 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research protocols for both parent clinical trials were approved by the Institutional Review Boards of the participating institutions, and a parent of each infant provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}